15029-34-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-METHYL-PIPERAZIN-1-YL)-3-OXO-PROPIONITRILE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its complex structure allows it to be a key component in the development of new drugs, potentially contributing to the treatment of various medical conditions.
Used in Chemical Research:
In the field of chemical research, 3-(4-METHYL-PIPERAZIN-1-YL)-3-OXO-PROPIONITRILE serves as a valuable compound for studying its properties and potential reactions with other chemicals. This can lead to a better understanding of its behavior and possible applications in various chemical processes.
Used in Industrial Manufacturing:
3-(4-METHYL-PIPERAZIN-1-YL)-3-OXO-PROPIONITRILE may be utilized in industrial manufacturing processes, where its unique chemical properties can be harnessed to produce specific products or materials. Its role in these processes could be as a catalyst, a reactant, or a component in the final product, depending on the specific application.

InChI:InChI=1/C8H13N3O/c1-10-4-6-11(7-5-10)8(12)2-3-9/h2,4-7H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 16130-58-8 cyanoacetic acid chloride 
• 105-56-6 ethyl 2-cyanoacetate 
• 105-34-0 methyl 2-cyanoacetate 

Downstream Products

• 1352550-14-1 (E)-3-(4-hydroxyphenyl)-2-[(4-methylpiperazin-1-yl)-carbonyl]acrylonitrile 
• 1240621-03-7 1-aminomethyl-1-(4-methylpiperazinomethyl)cyclohexane 
• 1266894-94-3 C₁₃H₂₁N₃O 
• 1307896-04-3 (E)-3-(3-(4-amino-5-(4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-(4-methylpiperazine-1-carbonyl)acrylonitrile 
• 1413912-93-2 2-(4-methylpiperazine-1-carbonyl)-3-(4-(7-pivaloyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazin-2-ylamino)phenyl)acrylonitrile 

Relevant academic research and scientific papers

IMMUNOPROTEASOME INHIBITORS

Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold

Janus kinases are major drivers of immune signaling and have been the focus of anti-inflammatory drug discovery for more than a decade. Because of the invariable colocalization of JAK1 and JAK3 at cytokine receptors, the question if selective JAK3 inhibition is sufficient to effectively block downstream signaling has been highly controversial. Recently, we discovered the covalent-reversible JAK3 inhibitor FM-381 (23) featuring high isoform and kinome selectivity. Crystallography revealed that this inhibitor induces an unprecedented binding pocket by interactions of a nitrile substituent with arginine residues in JAK3. Herein, we describe detailed structure-activity relationships necessary for induction of the arginine pocket and the impact of this structural change on potency, isoform selectivity, and efficacy in cellular models. Furthermore, we evaluated the stability of this novel inhibitor class in in vitro metabolic assays and were able to demonstrate an adequate stability of key compound 23 for in vivo use.

Synthesis of perhydro-N-(2,2-disubstituted- 3-aminopropyl) heterocycles as potentially bioactive compounds and fragments for combinatorial chemistry

A new method for the preparation of perhydro- N - (2,2-disubstituted-3- aminopropyl) heterocycles that allows to obtain a large variety of corresponding derivatives with high to moderate yields using simple procedures is described.

Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases

The 3-aryl-2-cyanoacrylamide scaffold was designed as core pharmacophore for inhibitors of the Dengue and West Nile virus serine proteases (NS2B-NS3). A total of 86 analogs was prepared to study the structure-activity relationships in detail. Thereby, it turned out that the electron density of the aryl moiety and the central double bond have a crucial influence on the activity of the compounds, whereas the influence of substituents of the amide residue is less relevant. The para-hydroxy substituted analog was found to be the most potent inhibitor in this series with a Ki-value of 35.7 μM at the Dengue and 44.6 μM at the West Nile virus protease. The aprotinin competition assay demonstrates a direct interaction of the inhibitor molecule with active centre of the Dengue virus protease. The target selectivity was studied in a counterscreen with thrombin and found to be 2.8:1 in favor of DEN protease and 2.3:1 in favor of WNV protease, respectively.